Figure 6: Heterozygous CTNND1 loss correlates with loss of expression and decreased patient survival. | Nature Communications

Figure 6: Heterozygous CTNND1 loss correlates with loss of expression and decreased patient survival.

From: p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis

Figure 6

(a) Immunohistochemistry (IHC) showing p120 and LaminA/C expression in human ductal carcinoma in situ (DCIS), invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Scale bar, 50 μm. (b) Box plot showing the relation between CTNND1 copy-number status (CN) and p120 mRNA expression. Shown are heterozygous (het), neutral (neut), gain and amplified (amp) CN status. Statistical significance was determined using pair-wise Tukey’s testing with the neutral copy-number group. ***P<0.001. (c)Tissue micro-array (TMA) cores of human breast cancer were stained and scored for p120. Shown are representative images of tumours neutral and heterozygous for CTNND1 that were scored as positive (retained) or negative (lost) for p120 protein expression. Scale bar, 100 μm. (d) Quantification of p120 expression correlated to CTNND1 copy number (CN) of TMA cores of human mammary carcinomas. Significance was determined using the Fisher’s exact test. (e) IHC showing p120 expression in human breast carcinomas with heterozygous genomic loss of CTNND1. Note the abnormal nuclear morphology in p120-deficient tumour cells (arrowheads) compared with p120 expressing cells (arrow). Scale bar, 50 μm. (f) Kaplan–Meier curve showing disease-specific survival of breast cancer patients displaying neutral CTNND1 CN (grey; n=1,773) or heterozygous loss of CTNND1 (blue; n=109). Statistical significance was determined using the log-rank test. Censored events are shown as dots and depicted between parentheses.

Back to article page